A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-Agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLD
- 09 Dec 2017 The efficacy and safety data will be presented at the meeting.
- 09 Dec 2017 Trial design presented at the 40th Annual San Antonio Breast Cancer Symposium
- 05 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.